XML 30 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Collaborative Agreements (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2018
USD ($)
Nov. 30, 2013
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Collaborative Agreements                          
Revenue recognized     $ 55,293,000 $ 48,768,000 $ 44,130,000 $ 34,046,000 $ 32,644,000 $ 20,596,000 $ 21,309,000 $ 16,696,000 $ 182,237,000 $ 91,245,000 $ 36,930,000
Deferred reimbursements     8,906,000       10,156,000       8,906,000 10,156,000  
Accounts payable, accrued expenses, and other current liabilities     120,373,000       $ 80,625,000       120,373,000 $ 80,625,000  
Collaborative Arrangements                          
Collaborative Agreements                          
Conditional aggregate payments per indication $ 86,500,000                        
Collaboration Agreement, Discovery Program Fee     10,000,000.0               10,000,000.0    
Payments for collaborative agreement $ 7,000,000                        
Collaborative Arrangements | GSK                          
Collaborative Agreements                          
Payments for collaborative agreement                     1,500,000    
Accrued payments for collaborative arrangement     4,000,000.0               4,000,000.0    
Revised Agreement | GSK                          
Collaborative Agreements                          
Upfront payment received   $ 0                      
Potential milestone payments upon achievement of post-approval and sales-based milestones   $ 40,000,000                      
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones   8                      
Revenue recognized                     15,500,000    
Deferred reimbursements     10,200,000               10,200,000    
Accounts payable, accrued expenses, and other current liabilities     $ 5,200,000               $ 5,200,000